LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-3)

Lilly

Status and phase: Begins enrollment in 1 month; Phase 2

Conditions: Ulcerative Colitis (UC); Ulcerative Colitis, Active Severe; Ulcerative Colitis, Active Moderate

Treatments: Drug: Placebo; Drug: LY4268989

Study type: Interventional

Funder types: Industry

Identifiers

NCT07415044

EU Trial (CTIS) Number (Other Identifier)

27589

J6E-MC-KWAM (Other Identifier)

Details and patient eligibility

About

The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC). The study drug will be administered orally.

The study will last up to approximately 108 weeks, excluding screening.

Enrollment: 1,431 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have had an established diagnosis of ulcerative colitis (UC) for ≥3 months prior to randomization, which includes endoscopic evidence of UC
• Have moderately to severely active UC defined by a Modified Mayo Score (mMS) of 5 to 9 with an Endoscopic Score (ES)≥2 confirmed by central reader and rectal bleeding (RB)≥1
• Have evidence of UC extending proximal to the rectum
• Have documented evidence of having had a surveillance colonoscopy within 1 year, or according to local guidelines, to evaluate for polyps, dysplasia, or malignancy, prior to randomization, if the participant has a history of UC symptoms for more than 8 years
• Have an inadequate response to, loss of response to, or intolerance to at least one conventional medication (including corticosteroids) or one advanced therapy (including biologics, Janus Kinase (JAK) inhibitors, or sphingosine-1-phosphate (S1P) immunomodulators). Participants with inadequate response to vedolizumab are excluded
• Must meet contraception requirements

Exclusion criteria

• Have a current diagnosis of

  • Crohn's disease
  • Inflammatory Bowel Disease (IBD unclassified) (formerly known as indeterminate colitis), or
  • primary sclerosing cholangitis

• Have an inherited immunodeficiency syndrome or known monogenic cause of UC-like colonic inflammation

• Have had or will need bowel resection or intestinal or intra-abdominal surgery

• Have evidence of toxic megacolon, intra-abdominal abscess, or stricture or stenosis within small bowel or colon that cannot be traversed by a colonoscope or that are symptomatic

• Have any prior or current evidence of cancer gastrointestinal (GI) tract, or specified lesions with increased risk of GI malignancies

• Have a diagnosis or history of malignant disease within 5 years prior to randomization

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

1,431 participants in 3 patient groups, including a placebo group

LY4268989 Study Dose 1

Experimental group

Description:

LY4268989 administered orally

Treatment:

Drug: LY4268989

LY4268989 Study Dose 2

Experimental group

Description:

LY4268989 administered orally

Treatment:

Drug: LY4268989

Placebo Study Dose

Placebo Comparator group

Description:

Placebo administered orally

Treatment:

Drug: Placebo